glp 1 news One in 10 people may have resistance to GLP-1 diabetes drugs GLP-1 NEWS: A study of

With clinically meaningful weight loss and cardiovascular outcomes in patients with type 2 diabetes, GLP-1RAs were further assessed in patients with overweight or obesity without type 2 diabetes in the 2021 STEP-1 trial and 2022 SURMOUNT-1 trial

The Journal ofclinical investigation, 127(12), 42174227

The app combines structured nutrition guidance, light exercise routines, and progress tracking tools to help users navigate weight loss with greater clarity and consistency

Patel and Dr

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

CARDIOVASCULAR EFFECTS OF GLP-1 RAs IN HUMAN STUDIES Blood pressure and heart rate Circulating biomarkers and lipid profiles Carotid intima-media thickness LV function and reperfusion injury in patients with coronary artery disease Retrospective studies on cardiovascular outcomes A prospective randomized clinical trial with primary cardiovascular outcome: the ELIXA study Preclinical and preliminary clinical evidence has consistently revealed potential cardiovascular benefits from the administration of GLP-1 RAs